Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 5:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: RR Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Development of a Resiliency Training Program for Parents of Children With Autism Spectrum Disorder

NCT02995408
View directory record Official record
Conditions
Stress
Interventions
Relaxation Response Resiliency Program for Parents of Children with ASD
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 11, 2024 · Synced Sep 3, 2026, 5:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Strategies to Promote Cessation in Smokers Who Are Not Ready To Quit

NCT02905656
View directory record Official record
Conditions
Smoking Cessation
Interventions
Brief Advice, Motivational Interviewing, Rate Reduction, Pharmacological, MI+RR
Behavioral · Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
903 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 29, 2024 · Synced Sep 3, 2026, 5:19 AM EDT
Not yet recruiting Not applicable Interventional

WIN Ratio Analysis to Determine a Strategy of Non- Invasive SUpport for Respiratory Failure in the EmeRgency Department

NCT07558265
View directory record Official record
Conditions
Acute Hypoxic Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS)
Interventions
Non-Invasive Positive Pressure Ventilation, High Flow Nasal Oxygen
Device
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
2
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Sep 3, 2026, 5:19 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

An Assessment of the Zephyr BioPatch and Its Ability to Monitor Patient Position

NCT02548624
View directory record Official record
Conditions
Patient Positioning, Monitoring, Physiologic, Pressure Ulcer
Interventions
Zephyr BioPatch
Device
Lead sponsor
Medtronic - MITG
Industry
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Sep 3, 2026, 5:19 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Behavioral Activation and Risk Reduction for Stimulant Use Among Sexually Active Adolescents and Young Adults

NCT06444360
View directory record Official record
Conditions
HIV
Interventions
IMPACT, eSOC
Behavioral
Lead sponsor
Westat
Other
Eligibility
16 Years to 24 Years
Enrollment
360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
2
States / cities
Los Angeles, California • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 3, 2026, 5:19 AM EDT
Not yet recruiting Not applicable Interventional

A Resilience-Based Approach to Improve Long-term Quality of Life in Post-treatment Lymphoma Survivorship

NCT07013435
View directory record Official record
Conditions
Lymphoma
Interventions
Health Education Program, SMART3RP-Lymphoma
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 3, 2026, 5:19 AM EDT
Withdrawn Phase 2 Interventional

Proof of Concept Study Evaluating RNS60 in the Treatment of Relapsing Remitting Multiple Sclerosis

NCT01714089
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
RNS60 125 ml, RNS60 250 ml, Interferon beta 1a
Drug
Lead sponsor
Revalesio Corporation
Industry
Eligibility
18 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 5, 2016 · Synced Sep 3, 2026, 5:19 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Personalized Risk Estimation for Crohn's Disease (PRE-Crohn's): Implementation and Feasibility

NCT05332639
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Crohn Disease, Crohn Colitis, Crohn's Ileocolitis, Crohn's Gastritis, Crohn's Jejunitis, Crohn's Duodenitis, Crohn's Esophagitis
Interventions
Personalized Risk Estimation for Crohn's Disease (PRE-Crohn's) tool, Standard Crohn's Disease Education
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
14 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Sep 3, 2026, 5:19 AM EDT
Completed Phase 1Phase 2 Interventional

Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications

NCT02649790
View directory record Official record
Conditions
Relapsed/Refractory Multiple Myeloma (RRMM), Metastatic Colorectal Cancer (mCRC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Higher-Risk Myelodysplastic Syndrome (HR-MDS), Acute Myeloid Leukemia (AML), Newly Diagnosed Intermediate/High-Risk MDS
Interventions
KPT-8602, ASTX727, Dexamethasone
Drug
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
26
States / cities
Los Angeles, California • Pasadena, California • Aurora, Colorado + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Sep 3, 2026, 5:19 AM EDT
Completed Not applicable Interventional Results available

Capnography-Assisted Learned Monitored (CALM) Breathing Therapy for COPD

NCT04786184
View directory record Official record
Conditions
COPD
Interventions
CALM Breathing, Traditional outpatient PR
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Sep 3, 2026, 5:19 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pilot Evaluation of an Continuous Contactless Vitals Parameter Monitoring System Dozee VS

NCT05380102
View directory record Official record
Conditions
No Specific Medical Conditions or Disease States
Interventions
Telemetry monitoring, Continuous monitoring through Earlysense, Continuous monitoring through Dozee VS
Device
Lead sponsor
Turtle Shell Technologies Pvt. Ltd.
Industry
Eligibility
18 Years to 100 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Redmond, Washington
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Sep 3, 2026, 5:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Short-Term Rhodiola Rosea for Anaerobic Performance and Cognitive Function in Resistance-Trained Adults

NCT07225413
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Rhodiola rosea (low dose), Rhodiola rosea (high dose), Placebo capsules
Dietary Supplement
Lead sponsor
Jacksonville State University
Other
Eligibility
18 Weeks to 40 Weeks
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Jacksonville, Alabama
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Sep 3, 2026, 5:19 AM EDT
Not listed Phase 1 Interventional

Behavioral Activation and HIV Risk Reduction for Men Who Have Sex With Men With Crystal Meth Abuse

NCT01255280
View directory record Official record
Conditions
Crystal Methamphetamine Abuse, Crystal Methamphetamine Dependence
Interventions
Behavioral Activation Therapy and Risk Reduction Counseling (BAT-RR), Information, Motivation, Behavioral skills change approach to sexual risk reduction
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 31, 2012 · Synced Sep 3, 2026, 5:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Nicotine and Tobacco Message Framing to Change Smoking Behavior in Diverse Groups of Young Adult Smokers

NCT06644664
View directory record Official record
Conditions
Tobacco-Related Carcinoma
Interventions
Health Education, Interview, Smoking Cessation Intervention, Survey Administration, Text Message-Based Navigation Intervention
Behavioral · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years to 35 Years
Enrollment
292 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Sep 3, 2026, 5:19 AM EDT
Completed Phase 2 Interventional Results available

Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma

NCT00712582
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
Etoposide, carboplatin, ifosfamide, Rituximab, Ifosfamide, Etoposide, Carboplatin, Rituximab, Ifosfamide, Etoposide, Carboplatin, Stem Cell Collection, Mitoxantrone, Cyclophosphamide and etoposide, Carmustine
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 20, 2022 · Synced Sep 3, 2026, 5:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Integrated BA and HIV RR Counseling for MSM With Stimulant Abuse

NCT03175159
View directory record Official record
Conditions
Stimulant Abuse, HIV Prevention, Substance Abuse
Interventions
IMPACT, Standard of Care
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older · Male only
Enrollment
205 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
2
States / cities
Miami, Florida • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 24, 2024 · Synced Sep 3, 2026, 5:19 AM EDT
Completed Phase 2 Interventional Results available

A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile

NCT02702388
View directory record Official record
Conditions
Thyroid Cancer
Interventions
Lenvatinib, Lenvatinib matching placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
16
States / cities
La Jolla, California • San Diego, California • Torrance, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Sep 3, 2026, 5:19 AM EDT
Terminated Phase 4 Interventional Results available

A Pilot Study to Determine the Most Effective Dose of Arformoterol for Treating Acute Asthmatic Patients

NCT00819637
View directory record Official record
Conditions
Acute Asthma
Interventions
arformoterol (RR formoterol), placebo, levalbuterol
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 45 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated May 23, 2023 · Synced Sep 3, 2026, 5:19 AM EDT
Completed No phase listed Observational Results available

Effect of Opioids on Ventilation in Children With Obstructive Sleep Apnea

NCT03938259
View directory record Official record
Conditions
Respiratory Depression, Obstructive Sleep Apnea
Interventions
Fentanyl
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
2 Years to 8 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 25, 2024 · Synced Sep 3, 2026, 5:19 AM EDT
Completed Not applicable Interventional

Optimizing a Smartphone Application for Individuals With Eating Disorders

NCT02503098
View directory record Official record
Conditions
Eating Disorders, Binge Eating Disorder, Bulimia Nervosa
Interventions
Recovery Record adaptive smartphone application, Recovery Record standard smartphone application
Behavioral
Lead sponsor
Recovery Record Research
Industry
Eligibility
16 Years and older
Enrollment
3,340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
San Francisco, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Sep 3, 2026, 5:19 AM EDT
Completed Phase 1 Interventional

A Study of RO6870810/TEN-010 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndrome

NCT02308761
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions
RO6870810
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 10, 2017 · Synced Sep 3, 2026, 5:19 AM EDT
Completed Phase 4 Interventional

Relaxation Response Training for the Treatment of Rheumatoid Arthritis

NCT00056667
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Relaxation response and cognitive behavioral therapy, Relaxation response, RA education
Behavioral · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 16, 2014 · Synced Sep 3, 2026, 5:19 AM EDT
Terminated Phase 2 Interventional Results available

Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing Regimens

NCT01695330
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Subcutaneous bortezomib
Drug
Lead sponsor
Oncotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
West Hollywood, California
Source: ClinicalTrials.gov public record
Updated Jan 15, 2017 · Synced Sep 3, 2026, 5:19 AM EDT
Recruiting Phase 1 Interventional

Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)

NCT06977711
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma
Interventions
Loncastuximab, Roflumilast, Rituximab, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Sep 3, 2026, 5:19 AM EDT